EpiBiologics, Inc.
SAN MATEO, CA · Founded 2021 · CIK 0001968158 · Biotech · Private
Bispecific antibodies that selectively degrade extracellular proteins
epibiologics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $30M
- 1 Form D · Apr 2023
- 41 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 20
- 0 granted · 20 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $30,030,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2146 | Origin Life Sciences, Inc. | — | $2.9M |
| 2147 | KALION, INC. | — | $6.7M |
| 2148 | VIRONGY, LLC | — | — |
| 2149 | EpiBiologics, Inc. | — | $30M |
| 2150 | Egalet Corp | — | $42M |
| 2151 | Denali Medical II, Inc. | — | $4.0M |
| 2152 | KANNALIFE SCIENCES, INC. | — | $1.5M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Samuel BjorkDirector
- Alexandra CantleyDirector
- Jason ColomaDirector
- Rami HannoushDirector · Executive Officer
- Michael KavanaughDirector
- Ann Lee-KarlonDirector · Executive Officer
- Craig LichtensteinExecutive Officer
- Seiji MiyaharaDirector
- Mitchell MutzDirector · Executive Officer
- James WellsDirector
Patents
- Binding Agents And Uses Thereofapplication
- DEGRADATION OF cMET USING A BISPECIFIC BINDING AGENTapplication
- Degradation Of Egfr Using A Bispecific Binding Agentapplication
- Binding Agents And Uses Thereofapplication
- Compositions And Methods Of Use For Binding Agentsapplication
- Modified CH1 Heterodimeric Proteinsapplication
- Binding Agents And Uses Thereofapplication
- Binding Agents And Uses Thereofapplication
- Compositions And Methods Of Use For Binding Agentsapplication
- Degradation Of Cmet Using A Bispecific Binding Agentapplication
- Bispecific Antibodies For Soluble, Intractable And Multiple Targets And Tissue Selectivityapplication
- Degradation Of Egfr Using A Bispecific Binding Agentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.